header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

THE EFFECTS OF OSTEOGENIC PROTEIN-1 (OP-1) DEVICE (RHBMP-7: COLLAGEN 1 COMPOSITE) ON OSTEOPOROTIC FRACTURE HEALING IN RATS



Abstract

Introduction and Aims: There is good preliminary evidence that Bone Morphogenic Protein 7 (BMP-7) plays an integral role in fracture healing and metabolism of bone. It is not known, however, whether the implantation of an OP-1 device will enhance the rate of fracture healing in the presence of osteoporosis. The object of this study was to determine the effects of OP-1 on osteoporotic fracture healing in rats.

Method: An open fracture of the mid-shaft of the femur was created in 60, three months post-surgical ovarectomised female Sprague Dawley rats. Thirty rats had OP-1 device with CMC putty implanted into the fracture site and 30 rats had CMC putty implanted without OP-1. The fracture was stabilised with a 1.4mm K-wire. Muscle and skin closed. Ten rats from each group were sacrificed at three time points – 12, 20 and 31 days post-surgery, and bilateral femurs harvested. The fractured femurs were analysed by DEXA scanning, high-resolution radiography, cross-sectional area, biomechanical assessment and histology.

Results: There was a statistically significant acceleration of fracture healing with the use of OP-1 in DEXA, radiological, cross-sectional area and biomechanical analysis and a qualitative enhancement by histological analysis.

Conclusion: The results show that an OP-1 device can enhance fracture healing in the presence of osteoporosis in a rat.

These abstracts were prepared by Editorial Secretary, George Sikorski. Correspondence should be addressed to Australian Orthopaedic Association, Ground Floor, The William Bland Centre, 229 Macquarie Street, Sydney, NSW 2000, Australia.

At least one of the authors is receiving or has received material benefits or support from a commercial source.